Skip to main content
SpringerLink
Log in

Chemotherapy

  • Chapter
  • First Online:
Tumors of the Jugular Foramen

  • 871 Accesses

Abstract

The most frequent jugular foramen tumors (paragangliomas, schwannomas, and meningiomas) present poor or no clinical response to the chemotherapy agents. Controversial results of chemotherapy with doxorubicin, dacarbazine, and cyclophosphamide have been reported in the literature to treat paragangliomas. Sunitinib has also been used with promising antiangiogenic and immune effects. Several agents such as progesterone antagonist (mifepristone), tamoxifen, interferon-alfa, hydroxyurea, vincristine, cyclophosphamide, somatostatin analog (octreotid), epidermal growth factor receptor inhibitors (gefitinib), and platelet-derived growth factor receptor inhibitors (imatinib) have been tried to treat benign, recurrent, and malignant meningiomas. Unfortunately no agent demonstrates good response. Target chemotherapies with imatinib, erlotinib, gefitinib, and lapatinib have demonstrated partial responses in cases of chordomas. There is no current efficient chemotherapy for chondrosarcomas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schwaber MK, Glasscock ME, Nissen AJ, Jackson CG, Smith PG. Diagnosis and management of catecholamine secreting glomus tumors. Laryngoscope. 1984;94:1008–15.

    Article  CAS  PubMed  Google Scholar 

  2. Massey V, Wallner K. Treatment of metastatic chemodectoma. Cancer. 1992;69:790–2.

    Article  CAS  PubMed  Google Scholar 

  3. Patel SR, Winchester DJ, Benjamin RS. A 15-year experience with chemotherapy of patients with paraganglioma. Cancer. 1995;76:1476–80.

    Article  CAS  PubMed  Google Scholar 

  4. Gillon P, Godbert Y, Dupin C, Bubien V, Italiano A, Roubaud G. Long clinical benefit achieved in two patients with malignant paraganglioma treated by metronomic cyclophosphamide. Future Oncol. 2014;10(14):2121–5.

    Article  CAS  PubMed  Google Scholar 

  5. Cai Y, Li HZ, Zhang YS. Successful treatment of coexisting paraganglioma of the retroperitoneum and urinary bladder by intermediate-dose 131I-MIBG therapy: a case report. Medicine. 2015;94, e1686.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Makis W, McCann K, McEwan AJ, Sawyer MB. Combined treatment with 131I-MIBG and sunitinib induces remission in a patient with metastatic paraganglioma due to hereditary paraganglioma-pheochromocytoma syndrome from an SDHB mutation. Clin Nucl Med. 2016;41(3):204–6.

    Article  PubMed  Google Scholar 

  7. Hoye SJ, Hoar Jr CS, Murray JE. Extracranial meningioma presenting as a tumor of the neck. Am J Surg. 1960;100:486–9.

    Article  CAS  PubMed  Google Scholar 

  8. Ayeni SA, Ohata K, Tanaka K, Hakuba A. The microsurgical anatomy of the jugular foramen. J Neurosurg. 1995;83:903–9.

    Article  CAS  PubMed  Google Scholar 

  9. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009;9:231–40.

    Article  CAS  PubMed  Google Scholar 

  10. Sioka C, Kyritsis AP. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol. 2009;92:1–6.

    Article  CAS  PubMed  Google Scholar 

  11. Chargari C, Védrine L, Bauduceau O, Le Moulec S, Ceccaldi B, Magné N. Reappraisal of the role of endocrine therapy in meningioma management. Endocr Relat Cancer. 2008;15:931–41.

    Google Scholar 

  12. Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;113:2146–51.

    Article  CAS  PubMed  Google Scholar 

  13. Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86:840–4.

    Article  CAS  PubMed  Google Scholar 

  14. Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997;86:845–52.

    Article  CAS  PubMed  Google Scholar 

  15. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996;84:733–6.

    Article  CAS  PubMed  Google Scholar 

  16. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96:211–7.

    Article  CAS  PubMed  Google Scholar 

  17. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American brain tumor consortium study 01–08). Neuro Oncol. 2009;11:853–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109:63–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109:187–93.

    Article  CAS  PubMed  Google Scholar 

  20. Goldenberg RA, Gardner G. Tumors of the jugular foramen: surgical preservation of neural function. Otolaryngol Head Neck Surg. 1991;104:129.

    Article  CAS  PubMed  Google Scholar 

  21. Crumley RL, Wilson C. Schwannomas of the jugular foramen. Laryngoscope. 1984;94(6):772–8.

    Article  CAS  PubMed  Google Scholar 

  22. Bompas E, Le Cesne A, Tresch-Bruneel E, Lebellec L, Laurence V, Collard O, et al. Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). Ann Oncol. 2015;26:2168–73.

    Google Scholar 

  23. Lebellec L, Aubert S, Zaïri F, Ryckewaert T, Chauffert B, Penel N. Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses. Crit Rev Oncol Hematol. 2015;95(1):125–31.

    Article  PubMed  Google Scholar 

  24. Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, et al. Imatinib in advanced chordoma: a retrospective case series analysis. Eur J Cancer. 2015;51(17):2609–14.

    Article  CAS  PubMed  Google Scholar 

  25. Di Maio S, Yip S, Al Zhrani GA, Alotaibi FE, Al Turki A, Kong E, et al. Novel targeted therapies in chordoma: an update. Ther Clin Risk Manag. 2015;11:873–83.

    Google Scholar 

  26. Houessinon A, Boone M, Constans JM, Toussaint P, Chauffert B. Sustained response of a clivus chordoma to erlotinib after imatinib failure. Case Rep Oncol. 2015;8(1):25–9.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bloch O, Sughrue ME, Mills SA, Parsa AT. Signaling pathways in cranial chondrosarcoma: potential molecular targets for directed chemotherapy. J Clin Neurosci. 2011;18:881–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chairman of the Neurosurgical Department, Neurological Institute of Curitiba, Curitiba, Brazil

    Ricardo Ramina MD, PhD

  2. Chairman of the Neurosurgical Department, Eberhard Karls University, Tübingen, Germany

    Marcos Soares Tatagiba MD, PhD

Authors
  1. Ricardo Ramina MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcos Soares Tatagiba MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ramina, R., Tatagiba, M.S. (2017). Chemotherapy. In: Tumors of the Jugular Foramen. Springer, Cham. https://doi.org/10.1007/978-3-319-43368-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43368-4_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43366-0

  • Online ISBN: 978-3-319-43368-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation